Targeting colorectal cancer-associated bacteria: A new area of research for personalized treatments
Targeting colorectal cancer-associated bacteria: A new area of research for personalized treatments
复制标题
DOI：
10.1080/19490976.2016.1155020
复制
发表时间：
2016-01-01
期刊：
影响因子：
12.2
通讯作者：
Bonnet, R.
中科院分区：
文献类型：
--
作者：
Fais, T.;Delmas, J.;Bonnet, R.
大多数结直肠癌（CRC）病例是散发性的，许多研究表明肠道微生物群可能在CRC的发展中起着至关重要的作用。大肠杆菌是肠道微生物群的成员，经常与结直肠肿瘤相关。CRC-associated E.大肠杆菌菌株经常携带PKS基因组岛。这个基因组岛负责大肠杆菌素基因毒素的合成，这增加了CRC小鼠模型中的肿瘤数量。我们最近表明，靶向ClbP，一种参与大肠杆菌素合成的关键酶，在体外阻断了这种毒素的有害作用，并导致体内肿瘤数量的显着减少。总之，我们的研究结果表明，CRC的个性化治疗还应考虑与肿瘤相关的细菌，以限制其有害影响。
Most cases of colorectal cancer (CRC) are sporadic, and numerous studies have suggested that gut microbiota may play a crucial role in CRC development. Escherichia coli is a member of the gut microbiota frequently associated with colorectal tumors. CRC-associated E. coli strains frequently harbor the pks genomic island. This genomic island is responsible for the synthesis of colibactin genotoxin, which increases tumor numbers in CRC mouse models. We recently showed that targeting ClbP, a key enzyme involved in colibactin synthesis, blocks the deleterious effect of this toxin in vitro and leads to a significant decrease in tumor numbers in vivo. Altogether, our results suggest that the personalized treatment of CRC should also take into consideration the bacteria associated with the tumor in order to limit their deleterious effects.